Melphalan With or Without Siltuximab
Phase II Randomized Trial of Population PK Dosed Melphalan With Interleukin-6 Blockade With Siltuximab Vesrus BSA Based Melphalan in Patients With Multiple Myeloma Over Age 60 Undergoing Autologous Stem Cell Transplantation
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 215 patients (estimated)
- Sponsors
- Memorial Sloan Kettering Cancer Center
- Collaborators
- Recordati Pharmaceutical company
- Tags
- Monoclonal Antibody, Interleukin 6 (IL-6), Post-Autologous Stem Cell Transplant, Pre-Autologous Stem Cell Transplant, Randomization
- Trial Type
- Treatment
- Last Update
- 2 days ago
- SparkCures ID
- 2018
- NCT Identifier
- NCT06679829
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.